Veracyte Priced, Nasdaq: VCYT
Sells molecular diagnostic tests for thyroid cancer to reduce unnecessary surgeries.
Industry: Health Care
First Day Return: +1.9%
VCYT
Sells molecular diagnostic tests for thyroid cancer to reduce unnecessary surgeries.
| IPO Data | |
|---|---|
| IPO Date | 10/29/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $65 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Francisco, CA, United States |
| Founded | 2006 |
| Employees at IPO | 107 |
| Website www.veracyte.com | |
Veracyte (VCYT) Performance
